High-dose chemotherapy with autologous PBSCT as post-remission therapy for AML

被引：0
|
作者：
Harada, M
Gondo, H
Kawano, F
机构：
[1] Okayama Univ, Sch Med, Dept Internal Med 2, Okayama 7008558, Japan
[2] Kyushu Univ, Fac Med, Dept Internal Med 1, Fukuoka 812, Japan
[3] Natl Kumamoto Hosp, Dept Internal Med, Kumamoto, Japan
来源：
BONE MARROW TRANSPLANTATION | 2001年 / 27卷 / 03期
关键词：
D O I：
10.1038/sj.bmt.1702786
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：347 / 347
页数：1
相关论文
共 50 条
  • [1] High-dose chemotherapy with autologous PDSCT as post-remission therapy for AML
    M Harada
    H Gondo
    F Kawano
    [J]. Bone Marrow Transplantation, 2001, 27 : 347 - 347
  • [2] High-dose melphalan is an effective salvage therapy in AML patients relapsing after autologous PBSCT
    Bug, G
    Atta, J
    Klein, S
    Hertenstein, B
    Bergmann, L
    Boehrer, S
    Hoelzer, D
    Martin, H
    [J]. BONE MARROW TRANSPLANTATION, 2004, 33 : S237 - S237
  • [3] The role of autologous haematopoetic stem cell transplantation in post-remission therapy of AML
    Durakovic, N.
    Batinic, J.
    Sertic, D.
    Bojanic, I.
    Batinic, D.
    Golubic-Cepulic, B.
    Nemet, D.
    [J]. BONE MARROW TRANSPLANTATION, 2013, 48 : S392 - S393
  • [4] Optimal post-remission consolidation therapy in patients with AML
    Jimenez-Chillon, Carlos
    Dillon, Richard
    Russell, Nigel
    [J]. ACTA HAEMATOLOGICA, 2024, 147 (02) : 148 - 159
  • [5] Should older adults with AML receive post-remission therapy?
    Stone, Richard M.
    [J]. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2015, 28 (2-3) : 106 - 111
  • [6] Time to Count Recovery after Post-Remission Chemotherapy in AML Patients
    Paras, Gabrielle
    Othus, Megan
    Shaw, Carole M.
    Russell, Katie
    Halpern, Anna B.
    Appelbaum, Jacob S.
    Hendrie, Paul C.
    Walter, Roland B.
    Percival, Mary-Elizabeth M.
    [J]. BLOOD, 2022, 140 : 6080 - 6081
  • [7] High-dose idarubicin plus busulfan as conditioning regimen to autologous stem cell transplantation: Promising post-remission therapy for acute myeloid leukemia in first complete remission?
    Ming Hong
    Kou-Rong Miao
    Run Zhang
    Hua Lu
    Peng Liu
    Wei Xu
    Li-Juan Chen
    Su-Jiang Zhang
    Han-Xin Wu
    Hong-Xia Qiu
    Jian-Yong Li
    Si-Xuan Qian
    [J]. Medical Oncology, 2014, 31
  • [8] High-dose idarubicin plus busulfan as conditioning regimen to autologous stem cell transplantation: Promising post-remission therapy for acute myeloid leukemia in first complete remission?
    Hong, Ming
    Miao, Kou-Rong
    Zhang, Run
    Lu, Hua
    Liu, Peng
    Xu, Wei
    Chen, Li-Juan
    Zhang, Su-Jiang
    Wu, Han-Xin
    Qiu, Hong-Xia
    Li, Jian-Yong
    Qian, Si-Xuan
    [J]. MEDICAL ONCOLOGY, 2014, 31 (06)
  • [9] Post-remission therapy of adult acute myeloid leukaemia: One cycle of high-dose versus standard-dose cytarabine
    Fopp, M
    Fey, MF
    Bacchi, M
    Cavalli, F
    Gmuer, J
    Jacky, E
    Schmid, L
    Tichelli, A
    Tobler, A
    Tschopp, L
    VonFliedner, V
    Gratwohl, A
    [J]. ANNALS OF ONCOLOGY, 1997, 8 (03) : 251 - 257
  • [10] Differentiative therapy plus low dose chemotherapy as a post-remission maintenance treatment for poor prognosis AML and myelodysplastic syndrome patients.
    Ferrero, D
    Grasso, M
    Campa, E
    Campana, S
    Foli, C
    Borchiellini, A
    Pileri, A
    [J]. BLOOD, 2000, 96 (11) : 211B - 211B
12345